Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 1 5 versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 1 5 versus FLUDROCORTISONE ACETATE.
DEXONE 1.5 vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
1.5 mg orally once daily
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid